Kevin T Liou1, Connie Chen2, Nicholas Emard1, Kathleen A Lynch3, Yen Nien Hou1, Jun J Mao1. 1. Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Medicine, NYU Winthrop Hospital, Mineola, NY, USA. 3. Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
OBJECTIVE: Herbs and natural products are increasingly used by cancer patients for pain management, but few studies have examined their integration within conventional cancer care. This study describes the characteristics, experiences, and perspectives of cancer patients who were prescribed an herbal topical analgesic for pain management. DESIGN AND SETTING: Program evaluation of a pilot herbal dispensary at a National Cancer Institute-designated comprehensive cancer center. SUBJECTS: Cancer patients who were prescribed the Tibetree Pain-Relieving Plaster (PRP) by an integrative medicine physician. METHODS: Sociodemographic and clinical characteristics of patients were abstracted from medical records. Semistructured phone interviews were conducted 1-2 weeks after PRP prescription to evaluate patient experiences with using PRP for pain. Interviews were analyzed through thematic content analysis. RESULTS: From February 2019 to February 2020, 50 patients were prescribed PRP. Median age (range) was 63 years (21-86), 37 patients (74%) were female, 14 (28%) were non-White, and 38 (76%) were using oral analgesics. During interviews, the majority of patients reported that the PRP improved pain and health-related outcomes, was convenient to use, and addressed pain management needs that were not fulfilled by oral analgesics. However, a few patients described adverse experiences with PRP, including skin irritation. CONCLUSIONS: Understanding patient experiences and perspectives is a critical step toward evidence-based integration of herbs and natural products into cancer pain management. Findings from this program evaluation will inform the design of a randomized clinical trial on the efficacy and safety of PRP for pain in patients with cancer.
OBJECTIVE: Herbs and natural products are increasingly used by cancer patients for pain management, but few studies have examined their integration within conventional cancer care. This study describes the characteristics, experiences, and perspectives of cancer patients who were prescribed an herbal topical analgesic for pain management. DESIGN AND SETTING: Program evaluation of a pilot herbal dispensary at a National Cancer Institute-designated comprehensive cancer center. SUBJECTS: Cancer patients who were prescribed the Tibetree Pain-Relieving Plaster (PRP) by an integrative medicine physician. METHODS: Sociodemographic and clinical characteristics of patients were abstracted from medical records. Semistructured phone interviews were conducted 1-2 weeks after PRP prescription to evaluate patient experiences with using PRP for pain. Interviews were analyzed through thematic content analysis. RESULTS: From February 2019 to February 2020, 50 patients were prescribed PRP. Median age (range) was 63 years (21-86), 37 patients (74%) were female, 14 (28%) were non-White, and 38 (76%) were using oral analgesics. During interviews, the majority of patients reported that the PRP improved pain and health-related outcomes, was convenient to use, and addressed pain management needs that were not fulfilled by oral analgesics. However, a few patients described adverse experiences with PRP, including skin irritation. CONCLUSIONS: Understanding patient experiences and perspectives is a critical step toward evidence-based integration of herbs and natural products into cancer pain management. Findings from this program evaluation will inform the design of a randomized clinical trial on the efficacy and safety of PRP for pain in patients with cancer.
Authors: Ting Bao; Susan Q Li; Josh L Dearing; Lauren A Piulson; Christina M Seluzicki; Robert Sidlow; Jun J Mao Journal: Acupunct Med Date: 2018-02-10 Impact factor: 2.267
Authors: M Underwood; D Ashby; D Carnes; E Castelnuovo; P Cross; G Harding; E Hennessy; L Letley; J Martin; S Mt-Isa; S Parsons; A Spencer; M Vickers; K Whyte Journal: Health Technol Assess Date: 2008-05 Impact factor: 4.014
Authors: Caitlin C Murphy; Hannah M Fullington; Carlos A Alvarez; Andrea C Betts; Simon J Craddock Lee; David A Haggstrom; Ethan A Halm Journal: Cancer Date: 2018-04-12 Impact factor: 6.860
Authors: Connie Chen; Susan Q Li; Ting Bao; Lily Zhang; Christina Seluzicki; Jun J Mao Journal: Integr Cancer Ther Date: 2020 Jan-Dec Impact factor: 3.279
Authors: Mingxiao Yang; Raymond E Baser; Susan Q Li; Yen-Nien Hou; Kamyar Chong; Yi Lily Zhang; Irfan Hoque; Ting Bao; Jun J Mao Journal: Front Pharmacol Date: 2022-05-04 Impact factor: 5.988